Clinical Trial Detail

NCT ID NCT02393248
Title Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Incyte Corporation

endometrial cancer

lung squamous cell carcinoma


myeloproliferative neoplasm

multiple myeloma

transitional cell carcinoma

breast cancer

Advanced Solid Tumor

stomach cancer


Cisplatin + Gemcitabine + Pemigatinib

Docetaxel + Pemigatinib

Pemigatinib + Retifanlimab

Pemigatinib + Trastuzumab

Epacadostat + Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST